Nature Release: BrainStorm Cell Therapeutics Inc.'s NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease

NEW YORK & PETACH TIKVAH--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Nature Reviews Neurology, a Nature Publishing Group Journal, highlighted recently published preclinical research results indicating that stem cells, generated with Brainstorm’s NurOwn™ technology, provide hope for Huntington disease's patients.